BioSpace News Archive

Airway Therapeutics, Inc. (Airway), a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, announced the first patient dosed in Spain in its ongoing Phase 1b Trial of zelpultide alfa (rhSP-D) for preventative use in very preterm infants at risk for bronchopulmonary dysplasia (BPD).

Recce Pharmaceuticals Ltd, the Company developing new classes of synthetic anti-infectives, is pleased to provide an updated timeline on its clinical programs with several significant data read-outs in 2022 and 2023.

Spero Therapeutics, Inc. today announced that it will host a virtual R&D event on Thursday, October 6, 2022, at 11:30 a.m. Eastern Time.

Imunon , Inc. (NASDAQ: IMNN ) , a clinical-stage drug development company, reports that partial results from an ongoing non-human primate study designed to examine the immunogenicity of its proprietary PLACCINE vaccine support PLACCINE as a viable alternative to mRNA vaccines.

Codexis, Inc. today announced the appointment of Kevin Norrett as Chief Operating Officer (COO), effective immediately.

Urica Therapeutics, Inc. today announced the appointments of Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer and Vibeke Strand, M.D., MACR, FACP, Adjunct Clinical Professor, Division of Immunology/Rheumatology, Stanford University, to its Board of Directors.

CymaBay Therapeutics, Inc. today announced that three abstracts related to its seladelpar development program for the treatment of primary biliary cholangitis (PBC) will be presented at The Liver Meeting ® of the American Association for the Study of Liver Diseases (AASLD).

Gradalis, Inc. announced a peer-reviewed publication in Clinical Medicine Insights: Oncology demonstrating positive results from a pilot study investigating Vigil® in combination with a PD-L1 checkpoint inhibitor, durvalumab, in patients with advanced triple negative breast cancer or recurrent/refractory ovarian cancer.

LogicBio® Therapeutics, Inc., a pioneering clinical-stage genomic medicine company, announced that it has entered into a definitive agreement under which AstraZeneca Rare Disease will acquire LogicBio.

Kira Pharmaceuticals announced today that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for KP104, a first-in-class bifunctional biologic that selectively and synergistically targets the alternative and terminal complement pathways.